Skip to main content

Advertisement

SpringerLink
Log in

Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Advanced, but potentially still curable gastric cancer (stages IIIA, IIIB, or stage IV M0) is associated with very high recurrence rates after gastrectomy. The value of an extended lymph node dissection (ELND) remains unclear in this setting.

Methods

A resected gastric cancer data set was created through structured queries to the SEER 1973–2000 database. Relationships between the number of lymph nodes (LNs) examined and survival outcomes were analyzed for the stage subgroups characterized by the N categories N2 or N3, and transmural tumor extension (T categories T2b or T3).

Results

The study group encompassed 1,377 patients, including T2b/3N2 (n = 1,076) and T2b/3N3 stage subgroups (n = 301). Total LN count (or number of negative LNs examined; P < 0.0001), number of positive LNs (P < 0.0001), age (P < 0.0001), primary site (P = 0.0002), T category (P = 0.0271), race (P = 0.0301) and gender (P = 0.0261) were independent prognostic survival predictors. A cut point analysis yielded the ability to detect significant survival differences for LN numbers up to 30 (N2) or up to 40 (N3), always in favor of the higher number of LNs examined. Best long-term survival outcomes were observed with negative LN counts of more than 15 (N2) or more than 20 (N3).

Conclusions

Even in transmural or serosa-positive gastric cancer with advanced nodal involvement, more extensive LN dissection and analysis influences survival. Stage-based survival prediction depends on total LN number and number of negative LNs. The mechanism remains uncertain, but is not limited to stage migration. ELND during potentially curative gastrectomy is recommended even for advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.
FIG. 3.
FIG. 4.
FIG. 5.
FIG. 6.
FIG. 7.
FIG. 8.
FIG. 9.

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106–30

    Article  PubMed  Google Scholar 

  2. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr., Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218(5):583–92

    Article  PubMed  CAS  Google Scholar 

  3. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80(12):2333–41

    Article  PubMed  CAS  Google Scholar 

  4. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88(4):921–32

    Google Scholar 

  5. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg 1998; 187(6):597–603

    Article  PubMed  CAS  Google Scholar 

  6. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84(12):1602–9

    Article  PubMed  CAS  Google Scholar 

  7. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9(4):394–400

    Article  PubMed  Google Scholar 

  8. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000; 232(3):362–71

    Article  PubMed  CAS  Google Scholar 

  9. Roder JD, Bottcher K, Busch R, Wittekind C, Hermanek P, Siewert JR. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 1998; 82(4):621–31

    Article  PubMed  CAS  Google Scholar 

  10. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995; 82(3):346–51

    Article  PubMed  CAS  Google Scholar 

  11. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study [see comments]. Ann Surg 1998; 228(4):449–61

    Article  PubMed  CAS  Google Scholar 

  12. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79(9–10):1522–30

    Article  PubMed  CAS  Google Scholar 

  13. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group [see comments]. N Engl J Med 1999; 340(12):908–14

    Article  PubMed  CAS  Google Scholar 

  14. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997; 84(11):1567–71

    Article  PubMed  CAS  Google Scholar 

  15. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195(6):855–64

    Article  PubMed  Google Scholar 

  16. Hartgrink HH, Van De Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized dutch gastric cancer group trial. J Clin Oncol 2004; 22(11):2069–77

    Article  PubMed  CAS  Google Scholar 

  17. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005; 23(28):7114–24

    Article  PubMed  Google Scholar 

  18. Surveillance, Epidemiology and End Results (SEER) Program: public use data (1973–2002). 2005 [accessed April 2005]; Available from: http://www.seer.cancer.gov

  19. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual, 6th edn. New York: Springer Verlag, 2002

    Google Scholar 

  20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53:457–81

    Article  Google Scholar 

  21. Peto R, Pike MC. Conservatism in the approximation E(0-E)2/E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29:579–84

    Article  PubMed  CAS  Google Scholar 

  22. Cox DR. Regression models and life tables. J R Stat Assoc 1972; 29:187–220

    Google Scholar 

  23. Borie F, Plaisant N, Millat B, Hay JM, Fagniez PL. Appropriate gastric resection with lymph node dissection for early gastric cancer. Ann Surg Oncol 2004; 11(5):512–7

    Article  PubMed  CAS  Google Scholar 

  24. de Manzoni G, Verlato G, Roviello F, et al. The new TNM classification of lymph node metastasis minimises stage migration problems in gastric cancer patients. Br J Cancer 2002; 87(2):171–4

    Article  PubMed  Google Scholar 

  25. Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94(11):2862–6

    Article  PubMed  Google Scholar 

  26. Lee HK, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001; 88(10):1408–12

    Article  PubMed  CAS  Google Scholar 

  27. Dhar DK, Kubota H, Tachibana M, et al. Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. Oncology 2000; 59(1):18–23

    Article  PubMed  CAS  Google Scholar 

  28. Schwarz RE, Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol 2002; 28(3):214–9

    Article  PubMed  CAS  Google Scholar 

  29. Callahan MA, Christos PJ, Gold HT, Mushlin AI, Daly JM. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. Ann Surg 2003; 238(4):629–36; discussion 36–39

    PubMed  Google Scholar 

  30. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131(1):6–15

    Article  PubMed  Google Scholar 

  31. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21(19):3647–50

    Article  PubMed  Google Scholar 

  32. Peeters KC, Kattan MW, Hartgrink HH, et al. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 2005; 103(4):702–7

    Article  PubMed  Google Scholar 

  33. Hartgrink HH, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90(3):153–65

    Article  PubMed  Google Scholar 

  34. Hundley JC, Shen P, Shiver SA, Geisinger KR, Levine EA. Lymphatic mapping for gastric adenocarcinoma. Am Surg 2002; 68(11):931–5

    PubMed  Google Scholar 

  35. Song X, Wang L, Chen W, et al. Lymphatic mapping and sentinel node biopsy in gastric cancer. Am J Surg 2004; 187(2):270–3

    Article  PubMed  Google Scholar 

  36. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725–30

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology (RES), The Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA

    Roderich E. Schwarz

  2. Division of Biostatistics (DDS), City of Hope Cancer Center, Duarte, CA, 91010, USA

    David D. Smith

  3. Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA

    Roderich E. Schwarz

Authors
  1. Roderich E. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David D. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roderich E. Schwarz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwarz, R.E., Smith, D.D. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 14, 317–328 (2007). https://doi.org/10.1245/s10434-006-9218-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-006-9218-2

Keywords

Search

Navigation